The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...
During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ...
The study, which evaluated associations between tattoo exposures and melanoma incidence, was designed as a population-based ...
The FDA has accepted for priority review the biologics license application (BLA) of Orca-T, an investigational allogeneic ...
Julie Brahmer, MD, and David P. Carbone, MD, PhD, share insights on managing toxicities of immune checkpoint inhibitor therapies in non–small cell lung cancer (NSCLC).
In an interview with Targeted Oncology, Harpreet Singh, MD, chief medical officer at Precision for Medicine and former director of the Division of Oncology 2, US FDA, discusses the FDA's new draft ...
Ziftomenib showed significant efficacy in relapsed/refractory NPM1-mutant AML, achieving deep, durable responses in the KOMET-001 trial. The trial enrolled 92 patients, with 23% achieving complete ...
An expert discusses efforts to improve the tolerability and delivery of the MARIPOSA regimen, highlighting subcutaneous amivantamab from the Paloma studies and proactive skin care strategies from the ...
Innovative advancements in cell therapy enhance NK cells for solid tumors, aiming for effective treatments while prioritizing patient safety and clinical success.
Patients considering maintenance lurbinectedin with atezolizumab need comprehensive information about potential adverse effects to make informed treatment decisions with their hea ...
The rationale for offering maintenance lurbinectedin centers on a stark reality that patients with SCLC face: Only 40% to 50% of people who receive first-line treatment are well e ...
In June 2025, the FDA granted priority review to the sNDA of revumenib (Revuforj) in relapsed/refractory NPM1 -mutant acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results